DSM Inks Deal with QRxPharma for Pain Therapy

DSM Pharmaceutical Products has signed a deal with QRxPharma to supply its MoxDuo pain management capsules in the U.S..

DSM Pharmaceutical Products has signed a manufacturing and supply agreement with QRxPharma for the U.S. production of its MoxDuo pain management capsules through 2015.

The agreement covers the production of MoxDuo Capsules, an immediate-release Dual Opioid pain therapy, a patented 3:2 fixed ratio combination of morphine and oxycodone. DSM will supply commercial volumes upon marketing approval.

"We have had a very productive relationship with DSM over the years as we evolved MoxDuo Capsules through to NDA filing, and we are now looking forward to launching our product into the acute pain marketplace in the U.S. in 2012 with the manufacturing support of DSM," said Dr. John Holaday, managing director and chief executive officer, QRxPharma.